Traduction de «des numbers » (Français → Néerlandais) :

Fichier EMPLOPER Champs : CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, QUARTER_REGISTR, P1_Q_OR_F, P1_NUMBER_FTE_PAYED, P1_NUMBER_FTE_38_WEEK et P1_NUMBER_PERSONS
Bestand EMPLOPER Velden: CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, QUARTER_REGISTR, P1_Q_OR_F, P1_NUMBER_FTE_PAYED, P1_NUMBER_FTE_38_WEEK en P1_NUMBER_PERSONS

Fichier EMPLOPER Champs : CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, QUARTER_REGISTR, P1_Q_OR_F, P1_CODE_QUAL_FUNCTION, P1_NUMBER_FTE_PAYED, P1_NUMBER_FTE_38_WEEK et P1_NUMBER_PERSONS
Bestand EMPLOPER Velden: CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, QUARTER_REGISTR, P1_Q_OR_F, P1_CODE_QUAL_FUNCTION, P1_NUMBER_FTE_PAYED, P1_NUMBER_FTE_38_WEEK en P1_NUMBER_PERSONS

Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

139 It implies that community services should be which evaluates the number of full-time equivalents (FTE) of active offered whenever possible, while hospital servicess should be available physicians. For the first time, preliminary counts of the number of when ambulatory care cannot provide a good answer to the patient’s practising nurses by sector of activity are now available. needs.
139 It implies that community services should be physicians. For the first time, preliminary counts of the number of offered whenever possible, while hospital servicess should be available practising nurses by sector of activity are now available. when ambulatory care cannot provide a good answer to the patient’s needs.

CDC: Centers for Diseases Control and Prevention (USA) CJD: Creutzfeldt–Jakob disease Cp: Comprimé CSS: Conseil Supérieur de la Santé EACS: European Aids Clinical Society EPI: Equipements de protection individuelle. EPINet TM : Exposure Prevention Information Network (standardized methods for recording and tracking percutaneous injuries and blood and body fluid contacts) FDA: Food and Drug Administration EFPSU: European Federation of Public Service Unions ETP: Equivalent temps-plein FMP: Fonds des Maladies Professionnelles FTC: Emtricitabine GERES: Groupe d ‘Etudes sur le Risque d’Exposition des Soignants (France) HAART: Highly active anti retroviral therapy HOSPEEM: European Hospital and Healthcare Employers’ Association IgHB: Immunoglobulines anti-hépatite B IM: Intra-musculaire IMP: Institut médico-pédagogique INTI: Inhibiteur nucléosidique de la transcriptase inverse INNT: Inhibiteur non nucléosidique de la transcriptase inverse ISP (WIV): Institut Scientifique de Santé Publique LCR: Liquide céphalo-rachidien MR-MRS: Maison de repos – Maison de repos et de soins PCR: Polymerase chain reaction PI: Protease inhibitor (inhibiteur de protéase) PPE: Prophylaxie post-exposition QD: Quaque die (chaque jour) QO: Quartier opératoire SEPPT: Service Externe de Prévention et de Protection au travail SIDA: Syndrome de l'immunodéficience acquise SIPPT: Service Interne de Prévention et de Protection au travail SPF: Service Public Fédéral TDF: Tenofovir UI: Unité internationale UN xxxx : Four-digit numbers that identify hazardous substances assigned by United Nations VIH: Virus de l’immunodéficience humaine VHB: Virus de l’hépatite B VHC: Virus de l’hépatite C VHG: Virus de l’hépatite G VSI: Virus simien de l’immunodéficience 3TC: Lamivudine
EPINet TM : Exposure Prevention Information Network (standardized methods for recording and tracking percutaneous injuries and blood and body fluid contacts) FDA: Food and Drug Administration EFPSU: European Federation of Public Service Unions FOD (SPF): Federale OverheidsDienst FBZ: Fonds voor de BeroepZiekten FTC: Emtricitabine GERES: Groupe d ‘Etudes sur le Risque d’Exposition des Soignants (Frankrijk) HAART: Highly active anti retroviral therapy HBV: Hepatitis B virus HBIg: Hepatitis B-immunoglobulin HBe Ag: Hepatitis B-virus core-antigeen HBs Asn: Antistoffen tegen het oppervlakteantigeen van het hepatitis B-virus HCV: Hepatitis C virus HGR: Hoge Gezondheidsraad HGV: Hepatitis G virus HIV: Human immunodeficiency virus HOSPEEM: European Hospital and Healthcare Employers’ Association IDPB: Interne Dienst voor Preventie en Bescherming op het werk IU : International unit (viro titration) NRTI : Nucleoside reverse transcriptase inhibitor NNRTI : Non-nucleoside reverse transcriptase inhibitor OK: Operatiekwartier PBW: Preventie en Bescherming op het Werk PCR: Polymerase chain reaction PI : Protease inhibitor PEP: Post exposure prophylaxis PSO: Prik- en spatongeval (= accidentele contacten met bloed en andere lichaamsvochten) QD: Quaque die (elke dag) RNA: Ribonucleic acid RH: Rusthuis RVT: Rust- en verzorgingstehuizen SIV : Simian immunodeficiency virus (Immunodeficiëntievirus bij apen) TDF : Tenofovir UN xxxx: four-digit numbers that identify hazardous substances assigned by United Nations VAZG: Vlaams Agentschap Zorg en Gezondheid VTE: Voltijds equivalent WIV: Wetenschappelijk Instituut voor Volksgezondheid WZC: Woon- en zorgcentra 3TC: Lamivudine

- Murphy WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in
- Murphy WG, Foley M, Doherty C, Tierney G, Kinsella A, Salami A, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sanguinis 2008; 95:13-9.

Les 3 piliers de l’UDI: identification par le Global Trade Item Number (GTIN), base de données et codage (bar) et numérisation des produits
De 3 pijlers van UDI: identificatie via het Global Trade Item Number (GTIN), database en (bar)coding en scanning van producten

Nombre de grains Number of seeds
Aantal zaadjes Number of seeds

In this case the intent-to-treat analysis can give unrealistically narrow confidence intervals if substantial numbers of patients elect to have the treatment they were not randomized to receive 22 .
In this case the intent-to-treat analysis can give unrealistically narrow confidence intervals if substantial numbers of patients elect to have the treatment they were not randomized to receive 21 .

GRISSOM R.J., « The magic number. 7+2 : meta-meta-analysis of the probability of superior outcome in comparisons involving therapy, placebo, and control».
KANDEL E.R., « La biologie et le futur de la psychanalyse : un nouveau cadre conceptuel de travail pour une psychiatrie revisitée », L’Evolution Psychiatrique, 2002, 67 : 40-82.